Lightening Becker nevus with topical glycolic acid

Zhong, Yiping; Chen, Yongjun; Huang, Lining; Wang, Hui; Yan, Tingting; Yang, Bin; Man, Mao‐Qiang

doi:10.1016/j.jaad.2018.07.016

Cited by 11 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IXORA-S was a 52-week, phase 3b, multicentre, randomised, double-blind, head-to-head trial in which eligible patients with moderate-to-severe plaque psoriasis were randomised (1:1) to receive either IXE (160-mg starting dose administered as two 80-mg injections, then 80 mg every 2 weeks for 12 weeks followed by 80 mg every 4 weeks; N = 136) or UST (45-mg/90-mg weight-based dosing at weeks 0, 4 and every 12 weeks thereafter per label; N = 166) [ 20 , 21 ]. No concomitant psoriasis treatments were allowed during the trial.…”

Section: Methodsmentioning

confidence: 99%

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

Wasel

Thaçi

French

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

Wasel

Thaçi

French

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…The 30‐week treatment did not have a better effect than the 8‐week treatment, but the patient was not followed up for longer 17 . Zhong reported that topical application of 70% glycolic acid solution could reduce the hyperpigmentation of BN, without any recurrence during 3 months of follow‐up 24 …”

Section: Treatment For Bnmentioning

confidence: 98%

“…17 Zhong reported that topical application of 70% glycolic acid solution could reduce the hyperpigmentation of BN, without any recurrence during 3 months of follow-up. 24…”

Section: Topical Therapymentioning

confidence: 99%

An update on Becker's nevus: Pathogenesis and treatment

Zhou

Zheng

Hamblin

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Becker's nevus (BN) manifests as a hyperpigmented, sometimes hypertrichotic plaque/patch over the chest and shoulder, and it is in the category of benign cutaneous hamartomas. BN has elongation and fusion of the rete ridge, keratotic plugging, sebaceous hyperplasia, smooth muscle hyperplasia, and hyperpigmentation of the basal/suprabasal layer histologically. This article highlights all issues involved in pathogenesis and treatment options of BN. According to current research, postzygotic ACTB mutations induce BN and Becker's nevus syndrome (BNS). Although several therapy strategies were utilized to treat the pigmentary and hypertrichotic aspects of BN, no definitive standard treatment was identified to far, and further research is needed to better educate BN care.

show abstract

“…Tapinarof (GSK2894512) is a naturally derived stilbene particle that activates AhR, subsequently inducing the expression of barrier genes in keratinocytes and downregulating the Th 17 pathway, thereby possessing the potential for alleviating symptoms of AD [ 211 ]. In a recent phase II study, 247 patients with AD were randomized to receive tapinar of cream or vehicle for 12 weeks [ 213 ]. In addition to achieving improvement in terms of the Investigator’s Global Assessment (IGA) and Eczema Area and Severity Index (EASI), pruritus also improved (according to NRS), with differences between the active and vehicle arms beginning to unveil at week 2.…”

Section: Aryl Hydrocarbon Receptor Agonistsmentioning

confidence: 99%

Emerging Therapeutic Options for Chronic Pruritus

2020

View full text Add to dashboard Cite

Chronic pruritus, defined as an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks, is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to complex pathogenesis and profuse contributing factors, chronic pruritus therapy remains challenging. Regardless of the well-established antipruritic properties of classic pharmacotherapy (topical therapy, phototherapy and systemic therapy), these methods often provide insufficient relief for affected individuals. Owing to the growing interest in the field of pruritic research, further experimental and clinical data have emerged, continuously supporting the possibility of instigating novel therapeutic measures. This review covers the most relevant current modalities remaining under investigation that possess promising perspectives of approval in the near future, especially opioidergic drugs (mu-opioid antagonists and kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists and histamine H 4 receptor antagonists.

show abstract

Lightening Becker nevus with topical glycolic acid

Cited by 11 publications

References 1 publication

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)

An update on Becker's nevus: Pathogenesis and treatment

Emerging Therapeutic Options for Chronic Pruritus

Contact Info

Product

Resources

About